glp-1 covered by cigna Evernorth expands program to help employers curb costs Why GLP-1 Weight Loss Drugs

Description

POINT VALUE How to earn points 1Create an account and start earning

Yes, you lost weight, but it was nothing to write home about

[98], for instance, led a retrospective study of 39,275 patients with T2D on exenatide twice-daily and 381,218 patients on other glucose-lowering therapies

Group, Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study, Diabetes care, 35 (2012) 252258

A 2023 study out of the University of British Columbia linked GLP-1 agonists to a heightened risk of severe gastrointestinal problems. These problems include gastroparesis, pancreatitis, and bowel obstruction